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Purpose of the study
A correlation between HCV infection and metabolic disor-
ders, such as dyslipidemia and type II diabetes, has
emerged. High serum cholesterol and LDL levels were
demonstrated to enhance the probability of sustained
viral response (SVR) of chronic hepatitis C. Conversely,
insulin resistance impairs the SVR rates. Since HIV infec-
tion and antiretroviral therapies may also affect metabolic
parameters, we investigated the influence of baseline glu-
cose and lipid values on the outcome of HCV treatment in
HIV-1 infected subjects.
Methods
We retrospectively reviewed the charts of the 140 HIV/
HCV co-infected patients treated with an interferon-based
regimen at our outpatient clinic from 2002 to 2007.
Exclusion criteria were: alcohol abuse, HBV co-infection,
CD4 cell count <200 cells/ml, concomitant hypocholeste-
rolemic drugs, and suboptimal anti-HCV therapy. Fasting
glucose levels, total cholesterol, LDL and tryglicerides lev-
els were registered prior to treatment start.
Summary of results
Of the 55 patients enrolled in the study, 21 (38%) had
genotype 1, 29 (52.7%) genotype 2 or 3, and five (9%)
genotype 4. SVR was obtained in 29% (6/21) and 65%
(22/34) in genotype 1 and 'other than 1', respectively.
Hyperglycemia or diabetes was present at baseline in 15/
27 (56%) non-responders but only in 4/28 (14%) of
responders. In the multivariate analysis, the independent
predictors of SVR were: genotype other than 1 [adjusted
odds ratio (AOR) 5.45 (1.25–23.7), p 0.024], fasting glu-
cose > 100 mg/dL [AOR 0.11 (0.024–0.528), p 0.006],
and cholesterol levels > 200 mg/dL [AOR 8.37 (1.12–
62.31), p 0.038]. Moreover, 34/51 (67%) patients of our
cohort were defined lipodystrophic, mostly (27/51, 53%)
showing peripheral lipoatrophy without significant rela-
tion at univariate analysis with anti-HCV therapy
response.  (Table 1.)
Conclusion
In conclusion, our study identified in a HIV/HCV co-
infected population, hyperglycemia, serum cholesterol
and, at a lesser extent, LDL as predictors of response to
peg-IFN plus ribavirin therapy as previously reported in
HCV-infected subjects. A possible explanation is that the
entry of HCV into the cell is mediated by LDL-receptor
that could be down-regulated by high levels of total and
LDL-cholesterol, resulting in reduced HCV infectivity.
HIV/HCV co-infected patients display a complex pattern
of metabolic alterations in which viral features, host char-
acteristics and drug toxicity interact and influence each
other; prospective studies will better address this impor-
tant issue and the underlying mechanisms.
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Baseline characteristics Overall (n = 55) SVR (n = 28) no SVR (n = 27) p AOR 95% CI p
Age (years; SD) 43; 3.9 42; 4.3 44; 3.2 0.072 0.948 0.798–1.127 0.546
Sex (male) 46 (84%) 23 (82%) 23 (85%) 0.763
Patients on HAART 49 (89%) 24 (85%) 25 (92%) 0.421
Baseline CD4 cells/μL; SD 540; 298 536; 228 540; 356 0.184
HIV-RNA cp/mL <50 <50 <50
HCV genotype
1 21 (38%) 6 (21%) 15 (56%) reference reference reference reference
not 1 34 (62%) 22 (79%) 12 (44%) 0.019 5.457 1.256–23.721 0.024
HCV viremia (Log IU/mL); SD 5.87; 0.7 5.67; 0.8 5.96; 0.5 0.102
ALT (IU/L); SD 100; 60 104; 62 90; 57 0.261
BMI; SD 23.4; 2.2 23.6; 2 22.8; 3.2 0.460
Hyperglicemia or diabetes 19 (34%) 4 (14%) 15 (55%) 0.001 0.113 0.024–0.528 0.006
Cholesterol >200 mg/dL 10 (18%) 8 (28%) 2 (7%) 0.078 8.373 1.125–62.316 0.038
LDL >100 mg/dL 15 (27%) 10 (36%) 5 (18%) 0.062
Lipoatrophy 29 (53%) 13 (46%) 16 (59%) 0.455Page 2 of 2
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